Clinical trials

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Patent Law #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Systems biology, information, disease and drug discovery

Systems biology, information, disease and drug discovery By Professor Stephen Naylor Pharmaceutical companies are confronted with an urgent need to increase their lead compound and clinical candidate portfolios and to satisfy market demands for continued innovation and revenue growth. The lack of improved productivity and limited drug pipeline growth is… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Medicinal chemistry #Molecular medicine #Pathology #PCR #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

GENE EXPRESSION as a toxicological screening tool

GENE EXPRESSION as a toxicological screening tool By Dr Bruce Seligmann The use of microarray data in drug development and requirements for FDA audit and approval. Toxicological safety testing of compounds has not yet advanced to the point where measurement of gene expression is being incorporated in the internal decision… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pathology #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Tissue Microarray (TMA) – A step ahead in drug discovery

Tissue Microarray (TMA) - A step ahead in drug discovery By Dr CR Camozzi Estimation of the clinical importance, market size and therapy-related side-effects are key questions in drug development. The ever-rising costs of drug discovery and development ($800-1,500 million for a successful drug research project) together with demonstrated uncertainty… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Molecular medicine #Organic chemistry #Patent Law #PCR #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

The impact of early ADME profiling on drug discovery and development strategy

The impact of early ADME profiling on drug discovery and development strategy By Dr Jianling Wang and Dr Laszlo Urban The increased costs in the discovery and development of new drugs, due in part to the high attrition rate of drug candidates in development, has led to a new strategy… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #High Content Screening #Imaging #Isotope labelling #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Organic chemistry #Orphan drugs #Preclinical #Regulatory #RNA #Screening

Radiosynthesis – A vital role supporting drug development?

Radiosynthesis - A vital role supporting drug development? By Dave Roberts and Professor Bill Lockley The key in vivo drug metabolism and pharmacokinetic studies continue to be undertaken using radiolabelled versions of drug molecules. Traditionally, the preparation of these isotopically labelled compounds was largely the domain of specialist internal radiochemistry… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Gene therapy #Genomics #Lead discovery #Lead optimisation #Patent Law #Pharmacology #Preclinical #Screening #Stem cells #Therapeutics

Failure rates in drug discovery and development: will we ever get any better?

Failure rates in drug discovery and development: will we ever get any better? By William Bains Drug discovery is an expensive, slow and risky business. An analysis which takes into account projects which neither succeed nor fail suggests that it costs more than $1 billion to launch a technically successful… Read More

#Archive

#AI / data analytics / healthtech / informatics #Business #Clinical trials #Drug development

Getting Property Strategy Right in Biotech

Getting Property Strategy Right in Biotech By Martin Sylvester The global biotech industry is, according to a recent report by Ernst & Young, 'turning up' despite a relatively subdued recent climate. Recovery in the biotech sector during 2003 was almost six months ahead of predictions and overall growth continues apace. Read More

#Archive

#Analysis #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Imaging #Lead discovery #Pathology #PCR #Pharmacology #RNA #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Novel concepts and therapeutic options for the treatment of schizophrenia

Novel concepts and therapeutic options for the treatment of schizophrenia By Dr Karoly Nikolich and Dr Roman Urfer Schizophrenia affects a large number of individuals irrespective of social status and education. Current treatments of schizophrenia represent the second largest central nervous system (CNS) pharmaceutical market, exceeding $12 billion per year. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Pathology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Systems Biology – Precise phenotypic anchoring for drug target identification, validation and biomarker discovery

By Dr Peter C. Johnson and Dr Alan J. Higgins The pharmaceutical industry has not seen the hoped-for productivity gains from the various omics datastreams over the last decade. This article discusses how systems biology can exploit the natural interlinkages between these datastreams and put in place a powerful system… Read More

#Archive

#AI / data analytics / healthtech / informatics #Business #Clinical trials #Drug development #Drug discovery #Immunology / Virology & Vaccines #Lead discovery #Pharmacology #Regulatory #RNA

How can we build sustainable European biopharmaceutical companies?

By Professor Simon Turton, Henry Makansi and Nick Lowcock Business models for emerging bioscience companies come in and out of fashion with some regularity, not always with obvious reason. This article examines what strategies have worked for the leading biopharmaceutical firms in Europe to try to identify what lessons there… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Microfluidics #Organic chemistry #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Systems biology #Target validation

Functional cell-based high throughput drug screening

Functional cell-based high throughput drug screening By Professor Daniel T. Chiu and Professor Owe Orwar Cell-based assays are poised to assume an increasingly important role in drug screening and discovery. It is becoming apparent that simple binding assays and in vitro experiments are grossly insufficient for extrapolating the efficacy and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Molecular medicine #PCR #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Toxicology

Gene Expression: Analysis and Drug R&D

Gene Expression: Analysis and Drug R&D By Dr Ralph Sinibaldi It is clear that gene expression profiling systems have a role to play in many facets of drug discovery and development, but several questions remain. We take a look at the use of DNA microarray for gene expression or expression… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #Lead discovery #Protein chemistry / Proteomics #Sequencing #Therapeutics

Drug Discovery Spending – A Year In Review

Drug Discovery Spending - A Year In Review By Isaac Meek Drug In 2003, the research products market reported revenues of $23 billion, with a 7.5% growth rate over 2002. Although there are many consumers in this market, by far the greatest are drug discovery research groups. In recent history,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Target validation #Therapeutics #Toxicology

Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library

Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library By Andrea Kroenke, Anne Grabner, Dr Michael Hannus, Dr Christoph Sachse, Dr David Dorris and Dr Christophe Echeverri Libraries of siRNAs directed against predefined subsets of genes now offer the capacity to greatly accelerate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Pathology #Pharmacogenomics #Pharmacology #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Role of image informatics in accelerating drug discovery and development

Role of image informatics in accelerating drug discovery and development By Robert Dunkle There is a new category of informatics that is proving itself essential to the acceleration of drug discovery and development. Image informatics is the systematic use of image data as a means to help interpret experiments and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Pathology #Stem cells #System biology #Therapeutics #Toxicology

Protease Inhibitor Therapeutics for Respiratory Disease

Protease Inhibitor Therapeutics for Respiratory Disease By Dr Philip J. Barr Disruption of the natural equilibria between proteases and their cognate inhibitors is a common feature of inflammatory disease. When this occurs in the lung, the effects can lead to irreversible impairment of pulmonary function. Although protease inhibition has been… Read More

#Archive